daflon. For Cramps, Swollen, Heavy legs
The #1 non-prescription brand Doctors recommend for treating Venous Disease. 1
How does daflon work?
Venoactive treatments, like daflon, are designed to help improve our leg vein health by strengthening the tone of our veins, which continue to weaken as Chronic Venous Insufficiency progresses.
daflon has a dual mechanism of action 2 :
- Its anti-inflammatory action directly reduces pain and swelling.
- Its venoprotective properties protect the capillaries (tiny blood vessels) to improve microcirculation and venous tone for better vein health, as well as relieve symptoms such as leg pain and swelling.
Tackle leg pain from the inside
daflon is a clinically proven, effective and convenient oral treatment derived from immature oranges and specially formulated for maximum absorption. 2
This improved absorption means that daflon is able to tackle the root of the problem and effectively treat veins from the inside, hence improving the tone of veins.
This potentially protects against disease progression and provides relief from heavy and painful leg symptoms. 3
Demonstrated effect of daflon Over 8 weeks
4 weeks 4
8 weeks 4
Leg pain
50%
63%
Sensation of heaviness
50%
65%
Sensation of swelling
50%
63%
Relieves Symptoms
daflon is the #1 Doctor-recommended, non-prescription brand for treating the symptoms of chronic venous insufficiency. 1
Clinical studies have shown that daflon can reduce leg pain and sensations of heaviness and swelling by up to 50% after only one month of use, which further improves to 63-65% after two months of treatment.
To benefit from your daflon treatment, you should take your medication as recommended. Be sure to monitor your condition closely and speak with a healthcare professional if you have any concerns.
Why you should treat early
daflon is a venoactive drug treatment which, thanks to its venous anti-inflammatory and venoprotective actions, can potentially prevent the development and progression of Chronic Venous Insufficiency. 2 This progressive condition requires treatment from the earliest stages of disease. Lifestyle changes, compression stockings and using a venoactive drug treatment that tackles the root cause of the problem can help alleviate painful symptoms. By treating early with daflon, you can help relieve symptoms and prevent them from getting worse. 5
Convenient Oral Dosing
daflon can be used from the earliest signs and prevents the development and progression of the disease. 2
daflon. Ongoing treatment for mild-to-moderate Chronic Venous InsufficiencyOne Tablet Twice a DayBest results achieved at 2 months
daflon. Naturally sourced, scientifically prepared.
The active ingredient in daflon is a micronised purified flavonoid fraction (MPFF)6 containing 90% diosmin and 10% other flavonoids expressed as hesperidin.
daflon’s flavonoids are extracted from immature oranges that are rich in these naturally occurring plant chemicals. The compounds undergo a process of purification and refinement where the particles collide with each other at high speeds (micronisation), reducing them to tiny particles, less than 2 μm in size (micronised). These smaller particles are absorbed twice as easily by the body and are a key ingredient of daflon’s success as a treatment for improving vein health and tone in Chronic Venous Insufficiency and Hemorrhoids. 6
Safety Information:
daflon 500mg Safety Information
COMPOSITION*: Micronized purified flavonoid fraction 500mg: 450mg diosmin; 50mg flavonoids expressed as hesperidin. INDICATIONS*: Treatment of organic and functional chronic venous insufficiency of the lower limbs with the following symptoms: swollen legs; pain; nocturnal cramps. Treatment of chronic hemorrhoids and acute hemorrhoidal attacks. DOSAGE AND ADMINISTRATION*: In chronic conditions: 1000mg daily. In acute hemorrhoidal attacks: the dosage can be increased up to 3000mg daily. CONTRAINDICATIONS*: Hypersensitivity to the active substance or to any of the excipients. WARNINGS*: The administration of this product for the symptomatic treatment of acute haemorrhoids does not preclude treatment for other anal conditions. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed. Excipients: sodium-free. INTERACTIONS*: None. FERTILITY*/ PREGNANCY*. BREASTFEEDING*: Avoid use of this product during pregnancy. Breast feeding is not recommended. DRIVE & USE MACHINES*. UNDESIRABLE EFFECTS*: Common: diarrhoea, dyspepsia, nausea, vomiting. Rare: dizziness, headache, malaise, rash, pruritis, urticaria. Uncommon: colitis. Frequency not known: abdominal pain, isolated face, lip, eyelid oedema. Exceptionally Quincke’s oedema. OVERDOSE*. PROPERTIES*: Vascular protector and venotonic. Daflon 500mg acts on the return vascular system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance. PRESENTATION*: Pack of 30 film-coated tablets of Daflon 500mg. SERVIER(S) PTE LTD 67 Ubi Avenue 1, #06-09 StarHub Green, Singapore 408942. www.servier.com
*For complete information, please refer to the Singapore Package Insert.
References:
- IQVIA Daflon sales data MAT Q2 2021
- Adapted from Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. Int Angiol. 2018;37(3):181-254.1
- Garner RC, Garner JV, Gregory S, Whattam M, Calam A, Leong D. Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J Pharm Sci. 2002;91:32-40.
- Gilly R, Pillion G, Frileux C. Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology. 1994;9:67-70.
- Pascarella L, Lulic D, Penn AH, et al. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg. Eur J Vasc Endovasc Surg. 2008;35(1):102-110.
- Summary of Product Characteristics Daflon
2024